



Published by DiscoverSys

Postoperative bleeding in CABG patients: new study in southwest of Iran



CrossMark

Amanollah Heidari,¹ Mehdi Dehghani Firoozabadi,² Mohammad Ali Sheikhi^{3*}

ABSTRACT

Background: A common complication after Coronary Artery Bypass Grafting (CABG) is postoperative bleeding, which is considered as an important problem.

Objective: The aim of this study is to study only patients who have never used drugs above so that it can assess postoperative bleeding in CABG with the absence of high-risk medications related to postoperative bleeding. Method: 50 patients who were candidates for CABG surgery participated in the study. Inclusions criteria included who were candidates for CABG surgery, avoiding the use of blood-clotting drugs before surgery, avoiding the use of immunosuppressant, and the absence of an underlying medical condition such as kidney diseases. Patients with inflammatory, platelet diseases, or any coagulation disorder were excluded. All patients initially tested for hemoglobin, platelets and hemoglobin and INR. In addition to testing for hemoglobin, the amount of bleeding and packed red cell; frozen plasma and platelets were recorded.

Results: Fifty patients who were candidates for elective surgery, including 33 men (66%) and 17 women (34%) were enrolled in this study. The mean patient age was 8.70+57.9years old. Test showed that

mean hemoglobin level of patients before surgery was pre-operative of 1.5 + 12.4 g/dL, mean platelet was equal to 54.14 + 250.8 thousand/ μ L and an average international normalized ratio (INR) was equal to 0.12+1.07. The results after surgery also showed that: The total units of given packed red cell; frozen plasma and platelets were (3.14 + 1.90; 2.34 + 2.36 and 0.06 + 0.42). Also, postoperative hemoglobin was 1.30 + 10.30 g/dL, which significantly decreased compared to pre-operative hemoglobin. Bleeding in patients was observed with an average of 537.5 + 973 mL. Of course, the amount of bleeding in any patient was not caused further surgery,

Conclusion: That the use of some drugs surgery can be a good way to reduce the risk of bleeding after surgery or on-use of some drugs can reduce the risk of bleeding after surgery with a minimum of morbidity and mortality. It is suggested that other researchers after designing clinical trials and using lower doses for effective drugs such as Clopidogrel and compared to control groups, or different doses of the N-acetylcysteine drug be reported more documentation to improve the bleeding after surgery.

Keywords: Postoperative bleeding, CABG, Southwest of Iran

Cite This Article: Heidari, A., Firoozabadi, M., Sheikhi, M. 2016. Postoperative bleeding in CABG patients: new study in southwest of Iran. *Bali Medical Journal* 5(3): 400-403. DOI:10.15562/bmj.v5i3.294

INTRODUCTION

Cardiovascular disease (CVD) is one of the major health problems that are prevalent in Iran and will be followed by a lot of deaths.¹ Atherosclerosis, particularly in coronary heart causes heart failure and there is need to special treatment.²⁻³ Coronary Artery Bypass Grafting (CABG) surgery is one of the effective and standard methods for treatment of coronary heart disease.⁴⁻⁵ Although surgery is a reliable method to improve myocardial perfusion, but nevertheless there are multiple complications after the procedure.⁵⁻⁶ A common complication after CABG is postoperative bleeding, which is considered as an important problem⁷ and the most common complication in these patients leads to reoperation, so that the results of a study showed that postoperative bleeding with incidence of 58.7% is the main cause of reoperation which in 90% of cases has occurred within the first 24 hours after surgery.⁸ On the other hand, massive bleeding after CABG is a major cause of postoperative mortality.⁹

Although bleeding from chest tubes after cardiac surgery is normal, but arteries bleeding is raised as life-threatening condition which is usually caused by rupture or leakage from sutures. On the other hand, venous bleeding is more common than arteries bleeding and can be created due to inadequate surgical hemostasis or coagulation disorders.¹⁰ Cardiopulmonary bypass has many hemostatic effects.

Blood in contact with pipes and tanks pump is considered as a severe provocation to initiate inflammatory responses, and leads to activation of the hemostatic system.¹¹ However, inadequate surgical hemostasis is the most common cause of bleeding after Cardiopulmonary Bypass (CPB), but certainly coagulation disorders occur and can be unacceptable when it associated with micro vascular bleeding. Facing blood with oxygenators and CPB circuit causes platelet activation, degranulation and platelet aggregation. In addition, the relative thrombocytopenia

¹Department of Cardiac surgery, Atherosclerosis Research Center and Imam Hospital, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

²Department of anesthesiology, Shahid Sadoughi University of Medical Sciences-Yazd, Iran

³Department of Cardiac surgery, Atherosclerosis Research Center Golestan Hospital, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

*Correspondence to: Amanollah Heidari Department of Cardiac surgery, Atherosclerosis Research Center and Imam Hospital, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
dr.heidari.a@gmail.com

usually occurs after CPB due to thin the blood and aggregation, platelet adhesion and degradation.

The most common cause of extensive bleeding in cardiac surgery patients is fibrinolysis, and platelet inhibition activity of CPB, especially in elderly patients.¹² In addition to the economic burden, administration of blood products in cardiac surgery have important clinical outcomes, that increased hospital mortality, renal dysfunction, peri-operative infections, sepsis, and permanent impairment of quality of life and pulmonary dysfunction and prolonged mechanical ventilation are among these side effects.¹³⁻¹⁶ The use of some drugs before surgery also adds to the increased risk of bleeding. For example, clopidogrel is an antiplatelet drug that has an important place among cardiovascular drugs. The main application of the drug is in combination with aspirin in the prevention of obstruction in patients, who have been undergoing CABG.¹⁷

The aim of this study is to study only patients who have never used drugs above, so that it can assess postoperative bleeding in CABG with the absence of high-risk medications related to postoperative bleeding.

MATERIAL AND METHODS

After obtaining permission from the university ethics committee, 50 patients who were candidates for CABG surgery knowingly participated in this cross-sectional study with the personal consent in writing. Our hypotheses were that CPB can increased bleeding after CABG. Inclusion criteria included who were candidates for CABG surgery, avoiding the use of blood-clotting drugs before surgery, avoiding the use of immunosuppressant, and the absence of an underlying medical condition such as kidney diseases. Also, in order to remove the confounding factors, the patients with inflammatory, platelet diseases, or any coagulation disorder were excluded. Also, each of the patients was free to leave the study at any time. All patients initially tested for hemoglobin, platelets and hemoglobin and International Normalized Ratio (INR) and after the surgery, in addition to testing for hemoglobin, the amount of bleeding and packed red cell; frozen plasma and platelets were recorded. All the data were analyzed by SPSS software.

RESULTS

Five patients who were candidates for elective surgery, including 33 men (66%) and 17 women (34%) were enrolled. The mean patient age was $8.70+57.9$ years old. Tests showed that mean hemoglobin level of patients before surgery was preoperative of $1.5 + 12.4$ g/dL, mean platelet was equal to $54.14 + 250.8$ thousand/ μ L and an average

Table 1 Pre-Operative Details of 50 elective patients' candidate for CABG

Pre-Operative Details (n=50)	
Age	57.9 + 8.70
gender (%male)	66
preoperative hemoglobin	12.4 + 1.5
preoperative platelet $\times 10^3$	250.8 + 54.14
Preoperative INR	1.07 + 0.12

Table 2 Perioperative complications (transfusion requirements; amount of bleeding

Number of patients who need packed red cell, fresh frozen plasma, and platelete transfusion; Total amount of bleeding	
Packed Red cell (%)	46 (92%)
Total unis	3.14 + 1.9
Fresh Frozen plasma (%)	27 (54%)
Total unis	2.34 + 2.36
Platelet (%)	1 (2%)
Total unis	0.06 + 0.42
Bleeding of the patients (%)	50 (100%)
Total amount (mL)	973 + 537.5




Figure 1 Comparison of Pre and Post-Operative Hemoglobin

international normalized ratio (INR) was equal to $0.12+1.07$ (Table 1).

The results after surgery also showed that: The total units of given packed red cell; frozen plasma and platelets were $(3.14 + 1.90)$; $(2.34 + 2.36)$ and $(0.06 + 0.42)$ respectively (table 2). Also, postoperative hemoglobin was $1.30 + 10.30$ g/dL, which significantly decreased compared to preoperative hemoglobin (figure 1). Bleeding in patients was observed with an average of $537.5 + 973$ mL. Of course, the amount of bleeding in any patient was not caused further surgery.

DISCUSSION

According to the results, patients' hemoglobin level after surgery in patients undergoing CABG significantly reduced, and bleeding of these patients lead to

need for blood products, including packed red cell; has been frozen plasma and platelets. The importance of these findings show the postoperative complications in the ICU, because lack of attention to this issue can be associated with irreparable damage on the patients, and in addition to other problems in the ICU¹⁸, it increases even the risk of kidney and safety diseases.¹⁹

Obviously, one of the essential ways to compensate for bleeding is the use of blood products, but increased use of these products leads to increased risk of transfusion-transmitted diseases, as well as kidney, liver disorders and immune responses.²⁰ Risk of immune responses is more important in this respect that these patients following bypass pump have faced with acute inflammatory and safety changes and many factors, including interleukins and complement in these patients has changed, all of which helps the deteriorating conditions in kidney and liver of the patients.²¹

The risk of blood products in addition to the risk of bypass pump can increase the patients' morbidity and mortality. It should be noted that if patients have underlying comorbidities, this risk will be greater. For example, in cancer patients²² and Chronic Obstructive Pulmonary Disease (COPD) patients with immune disorders, inflammatory responses will be more.²³⁻²⁵ According to what was said finding a way to reduce this complication and minimize morbidity and mortality is prevention of increased bleeding after surgery of these patients with other methods. In fact, we can help to reduce the postoperative bleeding using a preoperative drug or the lack of the use of a drug (also with less dose and time).

The studies show that among existing drugs, Clopidogrel is one of the drugs with the most effect on the risk of bleeding.²⁶ Also using a combination of drugs, efforts are made to reduce the risk of bleeding. It has been observed that N-acetylcysteine drug is associated with reduced bleeding after CABG surgery.²⁷ However, this information needs for further studies.

CONCLUSION

According to the results of this study and other studies, we conclude that the use of some drugs surgery can be a good way to reduce the risk of bleeding after surgery or non-use of some drugs can reduce the risk of bleeding after surgery with a minimum of morbidity and mortality. It is suggested that other researchers after designing clinical trials and using lower doses for effective drugs such as Clopidogrel and compared to control groups, or different doses of the N-acetylcysteine drug be reported more documentation to improve the bleeding after surgery.

REFERENCES

1. Sheikhi, Mohammad Ali;Ebadi, Ahmad; Rahmani, Hossein. Importance of further recognition of atherosclerotic patient's candidate for CABG: predisposing factors for postoperative stroke. *Advances in Natural and Applied Sciences*, 2015, 9(3): 8-13.
2. Sheikhi, M. A., Ebadi, A., Ramezani, A., &Gholizadeh, B. From atherosclerosis to cabg. *International Journal of Bioassays*. 2016; 4(02), 3676-3681.
3. Soltanzadeh M, Ebad A, Pipelzadeh MR, Tabatabaei SK, Firouzabadi MD, Vasigh A, et al. Gabapentin may relieve post-coronary artery bypass graft pain: a double blind randomized clinical trial. *International Cardiovascular Research Journal*. 2011 Sep;5(3):79-82.
4. Mohammad Ali Sheikhi, Ahmad Ebadi, Behnam Gholizadeh and Khosrow Sharifi. Effects and Risks of Thoracic Epidural Anesthesia for Cardiac Surgery. *World Journal of Pharmaceutical Research*. Volume 4. 2015. Issue 8, 236-251.
5. Adel SM, Ramezani AA, Hydare A, Javaherizadeh H, Behmanesh V, Amanei V. Gender-related differences of risk factors among patients undergoing coronary artery bypass graft in Ahwaz, Iran. *Saudi medical journal*. 2007;28(11):1686-9.
6. Goa F, Yao K, Tsai C, Wang K. Predictors of health care needs in discharged patients who have undergone coronary artery bypass graft surgery. *Heart Lung*. 2009. 38(3):182.
7. Abbaslo MR, Eghtesadi, Araghi P, zafarAsodeh A. The Comparison of re-relationship between preoperative bleeding time and postoperative bleeding in patients undergoing coronary artery bypass graft. *JAUMS*. 2004.1(4): 222-17.
8. Gregory AN, Daniel TE. A Comparison of Bleeding and Transfusion in patients who undergo coronary artery bypass grafting via sternotomy with and without cardiopulmonary bypass. *J CardiothoracVascAnesth*. 2003;17: 447-51.
9. Biancari F, Mikkola R, Heikkinen J, Lahtinen J, Airaksinen KE, Juvonen T. Estimating the risk of complications related to re-exploration for bleeding after adult cardiac surgery. *Eur J Cardiothoracic surgery*. 2012. 41(1):50-5.
10. Cohen LH. Cardiac surgical in the adult. USA: McGraw-Hill companies; 2008.
11. Nussmeier NA, Hauser MC, Sarwar MF, Grigore AM, Searies BE. In: Miller RD. Miller's Anesthesia. 7th ed. Philadelphia: Churchill Livingstone; 2010. p. 1889-975.
12. Pleym H, Wahba A, Videm V, Asberg A, Lydersen S, Bjella L, et al. Increased fibrinolysis and platelet activation in elderly patients undergoing coronary bypass surgery. *AnesthAnalg*2006;102(3):660-7.
13. Michalopoulos A, Tzelepis G, Dafni U, Geroulanos S. Determinants of hospital mortality after coronary artery bypass grafting. *Chest* 1999;115(6):1598-603.
14. Ranucci M, Pavesi M, Mazza E, Bertucci C, Frigiola A, Menicanti L, et al. Risk factors for renal dysfunction after coronary surgery: the role of cardiopulmonary bypass technique. *Perfusion* 1994;9(5):319-26.
15. Leal-Noval SR, Rincón-Ferrari MD, García-Curiel A, Herruzo-Avilés A, Camacho-Laraña P, Garnacho-Montero J, et al. Transfusion of blood components and postoperative infection in patients undergoing cardiac surgery. *Chest* 2001;119(5):1461-8.
16. Vamvakas EC, Carven JH. Allogeneic blood transfusion and postoperative duration of mechanical ventilation: effects of red cell supernatant, platelet supernatant, plasma components and total transfused fluid. *Vox Sang* 2002;82(3):141-9.
17. Moshfegh K, Redondo M, Julmy F, Willemin WA, Gebauer MU, Haerberli A, et al. Antiplatelet effects of clopidogrel compared with aspirin after myocardial infarction: enhanced inhibitory effects of combination therapy. *J Am CollCardiol* 2000; 36(3): 699-705.

18. Sheikhi, Mohammad Ali; Ebadi, Ahmad; Rahmani, Hossein. Sleep disorder in cardiac care units: a special look at noise and light effects. *International Journal of Bioassays*; 2014, 4.01: 3680-3685.
19. Firoozabadi, Mehdi Dehghani; EBADI, Ahmad. The effect of oral N-acetylcysteine on serum creatinine in chronic kidney diseases patients under CABG surgery. *Life Science Journal*; 2014, 11.4s.
20. Horvath, Keith A., et al. Blood transfusion and infection after cardiac surgery. *The Annals of thoracic surgery*. 2013; 95.6: 2194-2201.
21. Sheikhi, Mohammad Ali, et al. Cardiac surgery anesthesia and systemic inflammatory response. *International Journal of Bioassays*. 2015; 4.02: 3648-3655.
22. Sheikhi MA, Rahmani H. Inflammatory statuses of Non-Smoker Mustard Lung Patient candidate for Coronary artery bypass grafting Surgery. *Int. J. Pharm. Res. Allied Sci.*, 2016; 5(3):194-195.
23. Heidari A, Sheikhi MA, Rahmani H. Inflammatory status of Non-Smoker Sulphur Mustard exposed Patient with Cancer candidate for Coronary artery bypass grafting Surgery. *Int. J. Pharm. Res. Allied Sci.*, 2016, 5(3):196-198
24. Hossein Rahmani, IrajJavadi and Saeed Shirali. Respiratory Complications Due to Sulfur Mustard Exposure. *Int. J. Curr. Res. Acc. Rev.* 2016. 4(6): 143-149.
25. Chu, Michael WA, et al. Does clopidogrel increase blood loss following coronary artery bypass surgery?. *The Annals of thoracic surgery*, 2004, 78.5: 1536-1541.
26. Wang, Guyan, et al. N-acetylcysteine in cardiac surgery: do the benefits outweigh the risks? A meta-analytic reappraisal. *Journal of cardiothoracic and vascular anesthesia*, 2011, 25.2: 268-275.



This work is licensed under a Creative Commons Attribution